Carre frise 2014

Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR ( Cetuximab , Panitumumab) in the Treatment of Metastatic . Cetuximab , a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to . Description of Procedure or Service. Cetuximab (Erbitux , ImClone Systems) is a monoclonal antibody that binds to the epidermal growth. Treatment with cetuximab , an EGFR-targeting IgGmAb, in beneficial, yet limite clinical improvement for patients with head and neck . Epidermal growth factor receptor antibodies (EGFR) such as cetuximab have been approved for use as first-line management as well as salvage therapy for . We, therefore, performed a meta-analysis to determine the efficacy of first-line cetuximab versus bevacizumab for RAS and BRAF wild-type . Les perfusions de cétuximab (Erbitux ) peuvent être .